Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.
You may also be interested in...
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis suffered a major blow Aug. 6 when an Indian court dismissed its challenge of a key government provision that blocks the company from obtaining a patent for its oncologic Gleevec (imatinib)
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.